---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-123446"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2026-11-05T22:13:17+00:00"
generated_at: "2026-11-05T22:14:04.947505+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.87
calibrated_materiality_score: 0.87
confidence: "high"
source: SEC EDGAR
---

# ANI to buy Egetis for ~$560M cash offer at 27% premium; EMCITATE peak sales seen above $300M

## Summary
- SEK 11.25 per share cash offer values Egetis at ~SEK 5.6B ($559.9M), a 27% premium to the 60-day VWAP; enterprise value ~$434M after Egetis' $190M priority review voucher sale.
- Egetis board unanimously recommends; holders of ~42.2% of outstanding shares signed irrevocables; closing needs 90% tendered plus regulatory/FDI clearances, acceptance period ~Nov 20-Dec 18, 2026.
- EMCITATE (tiratricol) is the first and only approved MCT8 deficiency treatment - EU approval Feb 12, 2025, FDA Sept 28, 2026 - with >$300M peak sales potential and protection into mid-2045.
- $676M 364-day senior bridge from JPMorgan (ABR+1.75%, adjusted SOFR+2.75%) funds the offer and refinances ANI's existing term loans and Egetis debt; initially unsecured, then guaranteed/secured.
- ANI reports 3Q 2026 results the same morning ahead of an 8:00 a.m. ET call; Jefferies is ANI's sole financial advisor, Centerview advises Egetis, with Ropes & Gray and Mannheimer Swartling as counsel.

## SEC filing metadata
- accession: 0001104659-26-123446
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2026-11-05T22:13:17+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.87
- calibrated_materiality_score: 0.87
- confidence: high
- sec_items: 1.01, 8.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000110465926123446/0001104659-26-123446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000110465926123446/tm2628706d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-123446
- JSON: https://secwatch.observer/filing/0001104659-26-123446.json
- Plain text: https://secwatch.observer/filing/0001104659-26-123446.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.